HAND2-AS1

Summary

HAND2-AS1 (HAND2 antisense RNA 1, HGNC:48872) is a long non-coding RNA gene on chromosome 4q34.1.

Predicted to be involved in positive regulation of gene expression. Predicted to act upstream of or within with a positive effect on cardiac right ventricle morphogenesis. Predicted to act upstream of or within transcription elongation by RNA polymerase II. Predicted to be located in chromatin; cytoplasm; and nucleoplasm.

Source: NCBI Gene 79804 — RefSeq curated summary.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:48872
Approved symbol	HAND2-AS1
Name	HAND2 antisense RNA 1
Location	4q34.1
Locus type	RNA, long non-coding
Status	Approved
Aliases	DEIN, NBLA00301, FLJ11539
Ensembl gene	ENSG00000237125
Ensembl biotype	lncRNA
OMIM	617240
Entrez	79804
RNAcentral	URS0000A76676 — lncRNA, 4289 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 173 — 173 lncRNA

ENST00000502334, ENST00000502896, ENST00000502941, ENST00000503198, ENST00000503309, ENST00000503474, ENST00000504429, ENST00000504740, ENST00000505032, ENST00000505621, ENST00000505817, ENST00000507062, ENST00000507322, ENST00000507571, ENST00000507636, ENST00000508534, ENST00000508887, ENST00000509640, ENST00000509866, ENST00000510221, ENST00000510268, ENST00000510339, ENST00000511196, ENST00000511728, ENST00000512099, ENST00000512209, ENST00000512246, ENST00000512929, ENST00000512943, ENST00000514431, ENST00000515310, ENST00000515345, ENST00000515350, ENST00000515376, ENST00000515741, ENST00000561655, ENST00000616485, ENST00000642927, ENST00000643969, ENST00000644355, ENST00000644952, ENST00000645435, ENST00000645615, ENST00000645869, ENST00000646152, ENST00000647106, ENST00000647267, ENST00000686274, ENST00000686295, ENST00000686742, ENST00000687193, ENST00000688174, ENST00000688225, ENST00000688988, ENST00000689680, ENST00000689927, ENST00000690436, ENST00000690926, ENST00000691459, ENST00000692444, ENST00000701009, ENST00000701221, ENST00000701471, ENST00000702184, ENST00000702450, ENST00000785257, ENST00000785258, ENST00000785259, ENST00000785260, ENST00000785261, ENST00000785262, ENST00000785263, ENST00000785264, ENST00000785265, ENST00000785266, ENST00000785267, ENST00000785268, ENST00000785269, ENST00000785270, ENST00000785271, ENST00000785272, ENST00000785273, ENST00000785274, ENST00000785275, ENST00000785276, ENST00000785277, ENST00000785278, ENST00000785279, ENST00000785280, ENST00000785281, ENST00000785282, ENST00000785283, ENST00000785284, ENST00000785285, ENST00000785286, ENST00000785287, ENST00000785288, ENST00000785289, ENST00000785290, ENST00000785291, ENST00000785292, ENST00000785293, ENST00000785294, ENST00000785295, ENST00000785296, ENST00000785297, ENST00000785298, ENST00000785299, ENST00000785300, ENST00000785301, ENST00000785302, ENST00000785303, ENST00000785304, ENST00000785305, ENST00000785306, ENST00000785307, ENST00000785308, ENST00000785309, ENST00000785310, ENST00000785311, ENST00000785312, ENST00000785313, ENST00000785314, ENST00000785315, ENST00000785316, ENST00000785317, ENST00000785318, ENST00000785319, ENST00000785320, ENST00000785321, ENST00000785322, ENST00000785323, ENST00000785324, ENST00000785325, ENST00000785326, ENST00000785327, ENST00000785328, ENST00000785329, ENST00000785330, ENST00000785331, ENST00000785332, ENST00000785333, ENST00000785334, ENST00000785335, ENST00000785336, ENST00000785337, ENST00000785338, ENST00000785339, ENST00000785340, ENST00000785341, ENST00000785342, ENST00000785343, ENST00000785344, ENST00000785345, ENST00000785346, ENST00000785347, ENST00000785348, ENST00000785349, ENST00000785350, ENST00000785351, ENST00000785352, ENST00000785353, ENST00000785354, ENST00000785355, ENST00000785356, ENST00000785357, ENST00000785358, ENST00000785359, ENST00000785360, ENST00000785361, ENST00000785362, ENST00000829139, ENST00000829140

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000502334 — 5 exons

Exon	Start	End
ENSE00001787389	173530967	173531078
ENSE00002032834	173530800	173530850
ENSE00002267342	173536848	173536970
ENSE00004160924	173530451	173530539
ENSE00004160966	173538063	173538994

Expression profiles

Bgee: expression breadth ubiquitous, 178 present calls, max score 98.14.

FANTOM5 (CAGE): breadth broad, TPM avg 1.6430 / max 333.5732, expressed in 302 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
50635	0.9620	144
50634	0.3190	104
50633	0.0921	54
50631	0.0725	35
50632	0.0555	19
50637	0.0517	14
203423	0.0456	19
50636	0.0188	10
50640	0.0162	5
50638	0.0095	6

Top tissues by expression

280 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
decidua	UBERON:0002450	98.14	gold quality
muscle layer of sigmoid colon	UBERON:0035805	96.96	gold quality
body of uterus	UBERON:0009853	96.33	gold quality
apex of heart	UBERON:0002098	95.72	gold quality
right atrium auricular region	UBERON:0006631	95.58	gold quality
cardiac atrium	UBERON:0002081	94.37	gold quality
heart left ventricle	UBERON:0002084	94.35	gold quality
cardiac ventricle	UBERON:0002082	94.21	gold quality
gall bladder	UBERON:0002110	93.88	gold quality
lower esophagus muscularis layer	UBERON:0035833	93.80	gold quality
lower esophagus	UBERON:0013473	93.71	gold quality
endocervix	UBERON:0000458	93.41	gold quality
heart	UBERON:0000948	93.31	gold quality
descending thoracic aorta	UBERON:0002345	92.18	gold quality
left ovary	UBERON:0002119	92.17	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	92.13	gold quality
ascending aorta	UBERON:0001496	92.04	gold quality
stromal cell of endometrium	CL:0002255	91.94	gold quality
thoracic aorta	UBERON:0001515	91.87	gold quality
heart right ventricle	UBERON:0002080	90.57	gold quality
endometrium	UBERON:0001295	90.48	gold quality
myometrium	UBERON:0001296	89.89	gold quality
colonic epithelium	UBERON:0000397	89.71	gold quality
uterus	UBERON:0000995	89.63	gold quality
left uterine tube	UBERON:0001303	89.57	gold quality
ectocervix	UBERON:0012249	89.47	gold quality
right ovary	UBERON:0002118	88.79	gold quality
germinal epithelium of ovary	UBERON:0001304	88.26	gold quality
ovary	UBERON:0000992	88.03	gold quality
smooth muscle tissue	UBERON:0001135	88.03	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-10287	yes	105.64
E-ANND-3	yes	7.35

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 35)

• The characteristic expression pattern of DEIN suggests a specific role of this gene in the unique biology of stage IVS tumors and may help to molecularly define this special subtype of neuroblastoma. (PMID:18171985)
• Expression of HAND2 and DEIN genes in neuroblastoma is co-regulated by asymmetrical activity of this promoter and modulated by the activity of two cis-regulatory elements acting as weak repressors (PMID:19348682)
• The anti-tumorigenic effect of HAND2-AS1 in endometrioid endometrial carcinoma was mediated by down-regulating neuromedin U expression. (PMID:29107108)
• study demonstrated that HAND2-AS1 exerts a suppressive role in colorectal cancer by sponging miR-1275 and modulating KLF14 expression (PMID:30078677)
• LncRNA HAND2-AS1 inhibits non-small cell lung cancer migration, invasion and maintains cell stemness through the interactions with TGFB1. (PMID:30509963)
• lncRNA HAND2-AS1 may inhibit cancer cell proliferation, migration, and invasion in esophagus squamous cell carcinoma by regulating miRNA-21. (PMID:30520131)
• LncRNA HAND2-AS1 inhibits proliferation and promotes apoptosis of chronic myeloid leukemia cells by sponging with micRNA-1275. (PMID:30915755)
• Low HAND2-AS1 expression is associated with end-stage dilated cardiomyopathy. (PMID:31248315)
• Results identified a long noncoding RNA HAND2-AS1 that is highly expressed in liver cancer stem cells (CSCs). HAND2-AS1 promotes the self-renewal of liver CSCs via BMP signaling. (PMID:31334575)
• Screening of significant biomarkers related with prognosis of liver cancer by lncRNA-associated ceRNAs analysis. (PMID:31502679)
• LncRNA HAND2-AS1 sponging miR-1275 restrains proliferation and metastasis of breast cancer cells by regulating SOX7 expression. (PMID:31683462)
• lncRNA HAND2AS1 mediates the downregulation of ROCK2 in hepatocellular carcinoma and inhibits cancer cell proliferation, migration and invasion. (PMID:31922232)
• Haploinsufficiency of the basic helix-loop-helix transcription factor HAND2 causes congenital heart defects. (PMID:32134193)
• lncRNA HAND2-AS1 Inhibits Liver Cancer Cell Proliferation and Migration by Upregulating SOCS5 to Inactivate the JAK-STAT Pathway. (PMID:32155348)
• Long noncoding RNA HAND2-AS1 reduced the viability of hepatocellular carcinoma via targeting microRNA-300/SOCS5 axis. (PMID:32224127)
• LncRNA HAND2-AS1 represses cervical cancer progression by interaction with transcription factor E2F4 at the promoter of C16orf74. (PMID:32314545)
• LncRNA WTAPP1 promotes cancer cell invasion and migration in NSCLC by downregulating lncRNA HAND2-AS1. (PMID:32473628)
• Long non-coding RNA HAND2-AS1 inhibits gastric cancer progression by suppressing TCEAL7 expression via targeting miR-769-5p. (PMID:32952069)
• LncRNA HAND2-AS1 inhibits proliferation and promotes apoptosis of non-small cell lung cancer cells by inactivating PI3K/Akt pathway. (PMID:32975291)
• HAND2-AS1 Works as a ceRNA of miR-3118 to Suppress Proliferation and Migration in Breast Cancer by Upregulating PHLPP2. (PMID:33015182)
• Role of HAND2-AS1 in human tumors. (PMID:33096034)
• Long non-coding RNA HAND2-AS1 delays cervical cancer progression via its regulation on the microRNA-21-5p/TIMP3/VEGFA axis. (PMID:33139818)
• LncRNA HAND2-AS1 suppressed the growth of triple negative breast cancer via reducing secretion of MSCs derived exosomal miR-106a-5p. (PMID:33290256)
• Mesenchymal stem cell-originated exosomal lncRNA HAND2-AS1 impairs rheumatoid arthritis fibroblast-like synoviocyte activation through miR-143-3p/TNFAIP3/NF-kappaB pathway. (PMID:33549125)
• HAND2-AS1: A functional cancer-related long non-coding RNA. (PMID:33556872)
• lncRNA HAND2-AS1 overexpression inhibits cancer cell proliferation in hepatocellular carcinoma by downregulating RUNX2 expression. (PMID:33566427)
• Long noncoding RNA HAND2AS1/miR106a/PTEN axis resensitizes cisplatinresistant ovarian cells to cisplatin treatment. (PMID:34476500)
• HAND2-AS1 targeting miR-1208/SIRT1 axis alleviates foam cell formation in atherosclerosis. (PMID:34780888)
• Long Noncoding RNA HAND2-AS1 Suppresses Cell Proliferation, Migration, and Invasion of Bladder Cancer via miR-17-5p/KLF9 Axis. (PMID:35007433)
• Construction and Analysis of lncRNA-Associated ceRNA Network in Atherosclerotic Plaque Formation. (PMID:35463977)
• LncRNA HAND2-AS1 attenuates glioma cell proliferation, invasion and migration by targeting CDK6. (PMID:35548927)
• HAND2-AS1 rs2276941 Polymorphism Affecting the Binding of hsa-miR-1275 Is Associated with the Risk of Colorectal Cancer. (PMID:35575749)
• Bladder Cancer Progression Is Suppressed Through the Heart and Neural Crest Derivatives Expressed 2-Antisense RNA 1/microRNA-93-5p/Defective in Cullin Neddylation 1 Domain Containing 3 Axis. (PMID:36656536)
• HAND2-AS1 associates with outcomes of acute coronary syndrome and regulates cell viability of vascular endothelial cells. (PMID:37464074)
• Activation of HAND2-FGFR signaling pathway by lncRNA HAND2-AS1 in adenomyosisdagger. (PMID:38084072)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.